HomeCompareHTUS vs ABBV

HTUS vs ABBV: Dividend Comparison 2026

HTUS yields 12.37% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $57.1K in total portfolio value· pulled ahead in Year 5
10 years
HTUS
HTUS
● Live price
12.37%
Share price
$38.17
Annual div
$4.72
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.2K
Annual income
$2,673.45
Full HTUS calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HTUS vs ABBV

📍 ABBV pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHTUSABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HTUS + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HTUS pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HTUS
Annual income on $10K today (after 15% tax)
$1,051.29/yr
After 10yr DRIP, annual income (after tax)
$2,272.43/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $18,783.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HTUS + ABBV for your $10,000?

HTUS: 50%ABBV: 50%
100% ABBV50/50100% HTUS
Portfolio after 10yr
$73.8K
Annual income
$13,722.60/yr
Blended yield
18.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HTUS
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HTUS buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHTUSABBV
Forward yield12.37%3.06%
Annual dividend / share$4.72$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$45.2K$102.3K
Annual income after 10y$2,673.45$24,771.77
Total dividends collected$19.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HTUS vs ABBV ($10,000, DRIP)

YearHTUS PortfolioHTUS Income/yrABBV PortfolioABBV Income/yrGap
1$11,937$1,236.81$11,550$430.00+$387.00HTUS
2$14,152$1,379.77$13,472$627.96+$680.00HTUS
3$16,672$1,528.82$15,906$926.08+$766.00HTUS
4$19,522$1,683.18$19,071$1,382.55+$451.00HTUS
5← crossover$22,730$1,841.99$23,302$2,095.81$572.00ABBV
6$26,326$2,004.42$29,150$3,237.93$2.8KABBV
7$30,338$2,169.62$37,536$5,121.41$7.2KABBV
8$34,799$2,336.73$50,079$8,338.38$15.3KABBV
9$39,740$2,504.93$69,753$14,065.80$30.0KABBV
10$45,195$2,673.45$102,337$24,771.77$57.1KABBV

HTUS vs ABBV: Complete Analysis 2026

HTUSStock

The fund's sub-adviser seeks to achieve its investment objective, by using various proprietary analytical investment models that examine current and historical market data to attempt to predict the performance of the S&P 500 Index, a widely recognized benchmark of U.S. stock market performance that is composed primarily of large-capitalization U.S. issuers. The Sub-Adviser implements the fund’s S&P 500 investment strategy by taking positions in one or more ETFs that seek to track the performance of the S&P 500 (each an “S&P 500-related ETF”).

Full HTUS Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HTUS vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HTUS vs SCHDHTUS vs JEPIHTUS vs OHTUS vs KOHTUS vs MAINHTUS vs JNJHTUS vs MRKHTUS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.